Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Human respiratory syncytial virus Stories

2014-04-18 12:35:28

A Dana-Farber/Boston Children's and VA Hospital/University of South Florida team created the antiviral therapy, which harnesses the power of stapled peptide and nanoparticle technologies to thwart the respiratory virus New therapies are needed to prevent and treat respiratory syncytial virus (RSV) – a potentially lethal respiratory infection that can severely affect infants, young children and the elderly. Despite a wide range of anti-RSV efforts, there are no vaccines or drugs on the...

2014-04-15 04:20:50

LONDON, April 15, 2014 /PRNewswire/ -- reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV), today announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. Professor Schinazi has had a long and prestigious career in the industry having founded several successful biotechnology companies including Pharmasset, where he chaired...

2014-03-26 12:28:56

ANN ARBOR, Mich., March 26, 2014 /PRNewswire/ -- NanoBio Corporation today announced a licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology. Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal influenza and/or...

2014-03-25 08:29:52

Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhoea LONDON, March 25, 2014 /PRNewswire/ -- The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV) and influenza are characterised by variable response, poor tolerability and suboptimal dosing regimens, limiting their regular use and efficacy. Likewise, the development of resistance to almost every recommended antibiotic...

2014-03-19 08:29:00

BD Veritor(TM) System for Rapid Detection of RSV Receives 510(k) Clearance and CLIA Waiver FRANKLIN LAKES, N.J., March 19, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for nasopharyngeal swab specimens on the BD Veritor(TM) System...

2014-02-10 08:27:53

Study Aims To Evaluate Improvement in Lung Function after Treatment with NOxCureCF REHOVOT, Israel, February 10, 2014 /PRNewswire/ -- Advanced Inhalation Therapies (AIT Ltd.), a drug development company, announced today it added Schneider Children's Medical Center of Israel as the second site in its multicenter, open-label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). Schneider Children's is the largest children's...

2014-02-05 12:29:15

The feat bolsters rational vaccine design approach that could also be applied to other challenging viruses including HIV and influenza LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has...

2014-01-07 12:27:31

Enrollment in the Multicenter Trial Begins in Soroka Medical Center in Israel REHOVOT, Israel, January 7, 2014 /PRNewswire/ -- Advanced Inhalation Therapies (AIT Ltd.), an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). NOxCureCF is a specialized formulation of inhaled Nitric Oxide (NO) delivered using...

2014-01-06 04:21:45

In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics TOKYO, ROCKVILLE, Md. and EPALINGES, Switzerland, Jan. 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched...

Imaging Technology May Unlock Childhood Disease Mystery
2013-12-30 13:34:27

Georgia Institute of Technology By the time they're two, most children have had respiratory syncytial virus (RSV) and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis – which can require hospitalization and have long-term consequences. A new technique for studying the structure of the RSV virion and the activity of RSV in living cells could help...


Latest Human respiratory syncytial virus Reference Libraries

45_372e8ab43ffc45ec313edc65d2ef1af0
2011-02-23 17:56:27

Respiratory syncytial virus (RSV) causes respiratory tract infections and is a major cause of lower respiratory tract infection and hospital visits during infancy and childhood. For premature infants and infants with congenital heart disease there is a prophylactic medication. During winter months in temperate climates there is an annual epidemic. Infection in tropical climates is most common during the rainy season. 60% of infants, in the United States, are infected during their first...

More Articles (1 articles) »